Ractigen Therapeutics Closes An Additional $30 Million In Series A+ Funding To Push Development Of Its Rnaa Platform
Ractigen Therapeutics Closes An Additional $30 Million In Series A+ Funding To Push Development Of Its Rnaa Platform
01/27/22, 9:10 AM
Location
nantongMoney raised
$30 million
Industry
science and engineering
health care
Round Type
series a
Ractigen Therapeutics, a pioneer of the RNAa technology, today announced the closing of a Series A+ financing round totaling $30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, and Xianghe Capital. This latest round comes on the heels of a $18 million Series A investment in February 2021. Ractigen will use this capital to advance several programs from preclinical to clinical phase, as well as scale-up its oligonucleotide manufacturing capabilities.
Company Info
Location
nantong, jiangsu, china
Additional Info
Ractigen Therapeutics was founded in 2017 by pioneers of the RNAa technology including Dr. Long-Cheng Li and his longstanding colleagues Dr. Robert Place and Dr. Moorim Kang. Ractigen is a late-stage preclinical pharmaceutical company devoted to creating groundbreaking therapies based on the RNAa platform. RNAa utilizes short duplex RNAs, known as small activating RNAs (saRNA), to specifically up-regulate targeted endogenous genes for boosting therapeutic protein production. Supporting its core platform, Ractigen Therapeutics has created the SCAD delivery system allowing enhanced biodistribution throughout extrahepatic tissue and built a rich pipeline of first-in-class candidate medicines for patients with unmet genetic disorders.
Ractigen Therapeuticswww.ractigen.com
SOURCE Ractigen Therapeutics